Who are Licensed Spikevax Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mRNA-1273 Variant-containing Formulation, COVID-19 mRNA vaccine, mRNA-1273, mRNA-1283, Spikevax bivalent Original/Omicron BA.1, Moderna mRNA-1273 COVID-19 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/licensed-spikevax-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Licensed Spikevax Vaccine — Competitive Intelligence Brief

Licensed Spikevax Vaccine (Licensed Spikevax Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

phase 3 mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Licensed Spikevax Vaccine (Licensed Spikevax Vaccine) — ModernaTX, Inc.. Spikevax is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to protect against COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Licensed Spikevax Vaccine TARGET	Licensed Spikevax Vaccine	ModernaTX, Inc.	phase 3	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1283	mRNA-1283	ModernaTX, Inc.	marketed	mRNA vaccine	HPV16 and HPV18 antigens (E6 and E7 proteins)
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Licensed Spikevax Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/licensed-spikevax-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab